Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 47

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 47
---
ing or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities.

To ensure that we are not obligated to register as an investment company, we expect to comply with Rule 3a-2 of the U.S. Investment Company Act (“ICA Rule 3-a2”), which provides a one-year safe harbor from the definition of investment company to any issuer that has a bona fide intent to be engaged primarily, as soon as is reasonably possible, in a business other than that of investing, reinvesting, owning, holding, or trading in securities. Our Board has passed a resolution requiring that following the closing of the Merger, we are required to sell such shares of Telomir during the one-year period following the Merger, in accordance with ICA Rule 3-a2.

If the SEC or its staff does not believe that we complied with ICA Rule 3-a2, or there are changes to ICA Rule 3-a2, our business will be materially and adversely affected. In particular, we would be required to register as an investment company This could make it impractical for us to continue our business as currently conducted. Our ceasing to qualify for an exemption from registration as an investment company could materially and adversely affect the value of our shares and our ability to pay dividends in respect of our shares.

| 23 |

<div align='center'>THE MERGER</div>

This section and the section titled “The Merger Agreement” in this proxy statement describe the material aspects of the Merger, including the Merger Agreement. While MIRA believes that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should carefully read this entire proxy statement for a more complete understanding of the Merger and the Merger Agreement, including the Merger Agreement attached as Annex A, and the fairness opinion and valuation report of SKNY Pharmaceuticals, Inc. attached as Annex B, the valuation report for MIRA Pharmaceuticals Inc. is attached as Annex C, and the fairness opinion for the Merger attached as Annex D and the SKNY-1 License Agreement is attached as Annex Eto this proxy statement, and the other documents to which you are referred herein. See the section titled “Where You Can Find More Information” in this proxy statement.

Background of the Merger

On December 13, 2024, SKNY was incorporated in the state of Delaware